SEC Company Response from Bionano Genomics, Inc. (BNGO) (CIK 0001411690) (BNGO) — Aug 17, 2018
Bionano Genomics, Inc. (BNGO) (CIK 0001411690)
Date: Aug. 17, 2018 · CIK: 0001411690 · Accession: 0001193125-18-251876
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225970
Letter
Re:
August 17, 2018
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Bionano Genomics, Inc.
Registration Statement on Form S-1
File No. 333-225970
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Roth Capital Partners, LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it becomes effective at 4:30 PM, Eastern Time, on August 20, 2018, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective. In addition, this request supersedes in its entirety the Registrant’s prior request for acceleration submitted to the Commission on August 6, 2018.
The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:
(i) Date of preliminary prospectus: August 17, 2018;
(ii) Dates of distribution: August 17, 2018 through the date hereof;
(iii) Number of prospective underwriters and selected dealers to whom the preliminary prospectus was furnished: 22; and
(iv) Number of prospectuses so distributed: electronic 988, print 0.
The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
[Signature Page Follows]
ROTH CAPITAL PARTNERS, LLC
By:
/s/ Aaron M. Gurewitz
Name:
Aaron M. Gurewitz
Title:
Head of Equity Capital Market
Show Raw Text
CORRESP 1 filename1.htm CORRESP August 17, 2018 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Bionano Genomics, Inc. Registration Statement on Form S-1 File No. 333-225970 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Roth Capital Partners, LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it becomes effective at 4:30 PM, Eastern Time, on August 20, 2018, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective. In addition, this request supersedes in its entirety the Registrant’s prior request for acceleration submitted to the Commission on August 6, 2018. The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933: (i) Date of preliminary prospectus: August 17, 2018; (ii) Dates of distribution: August 17, 2018 through the date hereof; (iii) Number of prospective underwriters and selected dealers to whom the preliminary prospectus was furnished: 22; and (iv) Number of prospectuses so distributed: electronic 988, print 0. The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue. [Signature Page Follows] ROTH CAPITAL PARTNERS, LLC By: /s/ Aaron M. Gurewitz Name: Aaron M. Gurewitz Title: Head of Equity Capital Market